This is the place where you will be able to find Guidelines and Position Statements concerning Paediatric Anaesthesia.


While SPANZA endeavours to keep the information on its website (referred to as Website in this Disclaimer) accurate and relevant, it makes no warranties or representations of any kind concerning the accuracy or, clinical or other suitability of the information contained on the Website.

All such information is provided “as is”, and SPANZA takes no responsibility for matters arising from changed circumstances, or information or material which may have become available subsequently. Further, SPANZA makes no representations that the Website will operate uninterrupted or error-free, or that the Website or the hosting server are free from viruses or other forms of harmful computer code.
No Liability
To the extent permitted by law, SPANZA is not responsible for any loss, damage, injury to property or person, and costs incurred or suffered directly or indirectly in connection with use of the SPANZA Documents or the SPANZA Website. The permitted use of SPANZA Documents and the SPANZA Website is under the condition that users release SPANZA from all liability (including in negligence) in respect of such use.


If you would like SPANZA to consider the production of a statement, guideline or advice in any specific area, please CLICK HERE to submit an outline of your request detailing the area of interest and the issues being faced, and how such a document would support the work of anaesthetists and improve the care of children.

SPANZA Advisory on neurotoxicity of general anaesthesia for infants and children

Developed April 2023.

SPANZA are delighted to share with you the SPANZA Advisory on neurotoxicity of general anaesthesia for infants and children.

Please CLICK HERE to go to the document.

SPANZA would like to acknowledge the work of members in reviewing this document: A/ Prof Paul Lee-Archer, Qld; Prof Andrew Davidson, Vic; Dr Sebastian King, Vic; Dr Jonathan De Lima, NSW; Dr Fiona Macfarlane, Qld

SPANZA Sustainability Position Statement

Developed April 2023

SPANZA would like to thank members for the development of the 2023 SPANZA Sustainability Position Statement.

Please CLICK HERE to view the document.

This Position Statement has been developed by the SPANZA Sustainability Document Development Group 2022. (Dr Lee Beale, SA; Michael Clifford, Vic;  Dr Stephanie Cruice, Tas; Dr Paul Currant, NZ; Ben Hallett, Vic; Justin Hii, WA; Su May Koh, Vic; Rebecca McIntyre, Vic; Ian Miles, NSW and David Stoeter, Qld.)


ANZCA’s Professional Document: PG29 – “Guideline for the Provision of Anaesthesia Care to Children” and associated background paper have been published on ANZCA’s website.

Development of this updated guideline has been a substantial project and a significant collaboration between ANZCA and SPANZA. The original text of the document was developed by a SPANZA working group, and our processes overseen by the SPANZA Guidelines and Statements subcommittee.

CLICK HERE for PG29 document and HERE for background paper.

SPANZA would like to acknowledge the work of members in reviewing this document:

Dr Aimee Clark, NZ;  Dr Amanda Dalton, NZ;  Dr Patrick Farrell, ANZCA Councillor, NSW;  Dr Tanya Farrell, SPANZA Guidelines and Statements Committee, WA;  Dr David Linscott, Immediate past president, SPANZA, NZ;  Dr Ruth Matters, SPANZA Executive, Tas;  Dr Catherine Olweny, Chair SPANZA Guidelines and Statements Committee, Vic


ANZCA professional document PG07, Guidelines on Pre-Anaesthesia Consultation and Patient Preparation

ANZCA Safety and Quality committee has revised the Pg07 Document, Guidelines on Pre-Anaesthesia Consultation and Patient Preparation, specifically appendix 1 Fasting Guidelines.

SPANZA has contributed to this document to ensure it is consistent with the APAGBI guideline (see below) on clear fluid fasting for elective paediatric general anaesthesia endorsed by SPANZA.

A link to PG07 can be found HERE and CLICK HERE for the background paper.

APAGBI et al. guidelines:  Through SPANZA Guidelines and Statements Review Process, these guidelines have been endorsed by SPANZA in August 2018:



Subsequent to the FDA announcement on 20th April regarding the use of Codeine and Tramadol in children and in breastfeeding women ( SPANZA has asked groups of experts to review the literature and produce two advisory statements. The first is regarding the use of Tramadol in children. The second is regarding the use of Tramadol during breastfeeding and in the neonate. These documents arose from a request for advice from our membership, associated societies and medication regulatory authorities.

Tramadol and Breastfeeding: SPANZA’s Advisory on Tramadol – Use of Tramadol during breastfeeding and in the Neonate 15 June 2017

Tramadol and Children having Tonsillectomy: SPANZA’s Advisory on the use of tramadol in children having tonsillectomy under the age of 18 years in May 2017 in response to the new FDA contraindication



WFSA (World Federation of Societies of Anaesthesiologists) has developed the following statement, endorsed by SPANZA

Statement on Off-label use of medicines by anaesthesiologists

This document is referencing: “Off-Label” and Investigational Use Off Marketed Drugs, Biologics, and Medical
Devices – Information Sheet. U.S. FDA 2014



Consensus Statement on the Use of Anesthetic and Sedative Drugs in Infants and Toddlers, endorsed by SPANZA

Other Documents:

  • Press release announcing the statement, issued by SmartTots, a public-private  partnership of the International Anesthesia Research Society and the U.S. Food and Drug Administration.

You can find more information on the SmartTots website.